Oakland, CA4 Active Studies

Alzheimers Disease Clinical Trials in Oakland, CA

Find 4 actively recruiting alzheimers disease clinical trials in Oakland, CA. Connect with local research sites and explore new treatment options.

4
Active Trials
4
Sponsors
18,380
Enrolling

Recruiting Alzheimers Disease Studies in Oakland

RecruitingOakland, CANCT07177352

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies....

13,000 participants
Hoffmann-La Roche
View Study Details
RecruitingOakland, CANCT02693535

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or ...

4,200 participants
American Society of Clinical Oncology
View Study Details
RecruitingOakland, CANCT06212999

A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment wi...

960 participants
Incyte Corporation
View Study Details
RecruitingOakland, CANCT04166409

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated lo...

220 participants
National Cancer Institute (NCI)
View Study Details

About Alzheimers Disease Clinical Trials in Oakland

Alzheimer's disease is a progressive brain disorder that destroys memory, thinking skills, and the ability to carry out daily tasks. It is the most common cause of dementia, affecting over 6.7 million Americans age 65 and older. The disease is characterized by amyloid-beta plaques and tau tangles in the brain. Recent FDA approvals of anti-amyloid antibodies like lecanemab (Leqembi) and donanemab have opened a new era of disease-modifying treatments. Clinical trials are now exploring next-generation amyloid-clearing therapies, tau-targeting treatments, anti-inflammatory approaches, and combination strategies. Early-stage patients with mild cognitive impairment or early Alzheimer's are frequently sought for enrollment, and many trials now use blood-based biomarkers for screening.

There are currently 4 alzheimers disease clinical trials recruiting participants in Oakland, CA. These studies are seeking a combined 18,380 participants. Research is being sponsored by Hoffmann-La Roche, American Society of Clinical Oncology, Incyte Corporation and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Alzheimers Disease Clinical Trials in Oakland — FAQ

Are there alzheimers disease clinical trials in Oakland?

Yes, there are 4 alzheimers disease clinical trials currently recruiting in Oakland, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Oakland?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Oakland research site will contact you about next steps.

Are clinical trials in Oakland free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Oakland studies also compensate for your time and travel.

What alzheimers disease treatments are being tested?

The 4 active trials in Oakland are testing new therapies including novel drugs, biologics, and treatment approaches for alzheimers disease.

Data updated March 2, 2026 from ClinicalTrials.gov